Logo image of APPH.DE

APONTIS PHARMA AG (APPH.DE) Stock Fundamental Analysis

FRA:APPH - Deutsche Boerse Ag - DE000A3CMGM5 - Common Stock - Currency: EUR

11.3  -0.2 (-1.74%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to APPH. APPH was compared to 52 industry peers in the Pharmaceuticals industry. APPH has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, APPH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year APPH has reported negative net income.
In the past 5 years APPH reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: APPH reported negative operating cash flow in multiple years.
APPH.DE Yearly Net Income VS EBIT VS OCF VS FCFAPPH.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 5M -5M 10M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -14.50%, APPH is doing worse than 73.08% of the companies in the same industry.
With a Return On Equity value of -21.16%, APPH is not doing good in the industry: 69.23% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -14.5%
ROE -21.16%
ROIC N/A
ROA(3y)-5.52%
ROA(5y)-5.67%
ROE(3y)-10.91%
ROE(5y)-23.67%
ROIC(3y)N/A
ROIC(5y)N/A
APPH.DE Yearly ROA, ROE, ROICAPPH.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -10 -20 -30 -40 -50

1.3 Margins

APPH has a Gross Margin of 60.26%. This is in the lower half of the industry: APPH underperforms 63.46% of its industry peers.
APPH's Gross Margin has been stable in the last couple of years.
APPH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.58%
GM growth 5YN/A
APPH.DE Yearly Profit, Operating, Gross MarginsAPPH.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 20 -20 40 60

More info and screens

7

2. Health

2.1 Basic Checks

APPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
APPH has about the same amout of shares outstanding than it did 1 year ago.
APPH has a worse debt/assets ratio than last year.
APPH.DE Yearly Shares OutstandingAPPH.DE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2M 4M 6M 8M
APPH.DE Yearly Total Debt VS Total AssetsAPPH.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

APPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC6.91%
APPH.DE Yearly LT Debt VS Equity VS FCFAPPH.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 10M -10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 3.77 indicates that APPH has no problem at all paying its short term obligations.
APPH has a Current ratio of 3.77. This is amongst the best in the industry. APPH outperforms 94.23% of its industry peers.
APPH has a Quick Ratio of 2.74. This indicates that APPH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.74, APPH belongs to the top of the industry, outperforming 88.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.77
Quick Ratio 2.74
APPH.DE Yearly Current Assets VS Current LiabilitesAPPH.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

APPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -520.42%.
The Revenue for APPH has decreased by -33.67% in the past year. This is quite bad
The Revenue has been decreasing by -1.97% on average over the past years.
EPS 1Y (TTM)-520.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-33.67%
Revenue growth 3Y-1.97%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 28.19% on average over the next years. This is a very strong growth
APPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.19% yearly.
EPS Next Y106.55%
EPS Next 2Y49.51%
EPS Next 3Y34.52%
EPS Next 5Y28.19%
Revenue Next Year37.73%
Revenue Next 2Y26.5%
Revenue Next 3Y23.65%
Revenue Next 5Y21.19%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
APPH.DE Yearly Revenue VS EstimatesAPPH.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
APPH.DE Yearly EPS VS EstimatesAPPH.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APPH. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 27.05 indicates a quite expensive valuation of APPH.
Compared to the rest of the industry, the Price/Forward Earnings ratio of APPH is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.10, APPH is valued a bit more expensive.
Industry RankSector Rank
PE N/A
Fwd PE 27.05
APPH.DE Price Earnings VS Forward Price EarningsAPPH.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APPH.DE Per share dataAPPH.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

APPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as APPH's earnings are expected to grow with 34.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.51%
EPS Next 3Y34.52%

More info and screens

0

5. Dividend

5.1 Amount

APPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APONTIS PHARMA AG

FRA:APPH (3/7/2025, 7:00:00 PM)

11.3

-0.2 (-1.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07
Earnings (Next)03-26 2025-03-26/amc
Inst Owners45.55%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap96.05M
Analysts43.33
Price Target13.52 (19.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-10.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 27.05
P/S 1.51
P/FCF N/A
P/OCF N/A
P/B 3.09
P/tB 3.09
EV/EBITDA N/A
EPS(TTM)-0.76
EYN/A
EPS(NY)0.42
Fwd EY3.7%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS7.51
BVpS3.66
TBVpS3.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.5%
ROE -21.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.26%
FCFM N/A
ROA(3y)-5.52%
ROA(5y)-5.67%
ROE(3y)-10.91%
ROE(5y)-23.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.58%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover1.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.77
Quick Ratio 2.74
Altman-Z N/A
F-ScoreN/A
WACC6.91%
ROIC/WACCN/A
Cap/Depr(3y)150.19%
Cap/Depr(5y)135.8%
Cap/Sales(3y)5.98%
Cap/Sales(5y)4.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-520.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y106.55%
EPS Next 2Y49.51%
EPS Next 3Y34.52%
EPS Next 5Y28.19%
Revenue 1Y (TTM)-33.67%
Revenue growth 3Y-1.97%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year37.73%
Revenue Next 2Y26.5%
Revenue Next 3Y23.65%
Revenue Next 5Y21.19%
EBIT growth 1Y-392.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year122.57%
EBIT Next 3Y40.26%
EBIT Next 5Y33.27%
FCF growth 1Y-304.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-214.3%
OCF growth 3YN/A
OCF growth 5YN/A